Tue. Feb 20th, 2024

Agia in an 85-year old lady and rectal haemorrhage inside a 75-year old man), along with a additional than 10-fold improve of transaminases inside a 75-year old man. All the patients asked to return to their prior oral anticoagulant therapy with warfarin. On the 91 individuals who completed the 1-year adhere to up, 4 subjects (5.four ), all on 20 mg od, had NMCRB (two ladies) or minor bleeding (1 man and 1 woman), which did not demand discontinuation of therapy (Table II). No cerebral or peripheral arterial thromboembolic events have been observed.DOAC Dabigatran Adverse occasion (n) Severe thrombocytopenia (80 /L) (1) Epigastric discomfort and heartburn (4) Transient elevated gammaglutamyl ranspeptidase (1) Gastro-colic dyspepsia (15)TotalRivaroxabanSr lDOAC Rivaroxaban (n=103) 79 (50-94) 63 (61.1) 15 mg od: 92 (89.three) 20 mg od: 11 (10.7) 9 (8.7) two (1.9) four (three.9) 2 (1.9) 1 (1.0)4 (three.9) 3 (two.9)Table I – Adverse events and bleeding complications in patients on dabigatran and rivaroxaban for the duration of a 1-year adhere to up.TotalElevated transaminases (1)Main bleeding (n) Non-major clinically relevant bleeding (n)Gastrointestinal bleeding (1) Haemoptysis (two) Anal bleeding (1) Recurrent epistaxis (1) Macroscopic haematuria (2) Gengivorrhagia (1)Se rv iziMetrorrhagia (1) Rectal bleeding (1) Haemoptysis (1) Macroscopic haematuria (1) 2 two 7 four Mild epistaxis (1) Mild thrombocytopenia (8009/L) (1) 2 32 7 All (n=196) 78.five (50-94) 112 (57.1) 9 (4.five) three (1.5) 15 (7.7) six (three.0) 21 (10.7) 30 (15.3)() Episodes occurred within the identical patient; DOAC:Direct oral anticoagulants.Table II – Principal characteristics on the sufferers anticoagulated with DOAC.Dabigatran (n=93) 77 (56-89) 49 (52.six) 110 mg bid: 79 (84.9) 150 mg bid: 14 (14.1) Missed individuals, n Major bleeding, n Non-major clinically relevant bleeding, n Minor bleeding, n Non-bleeding side-effects, n Complications without the need of discontinuation of therapy, n with discontinuation of remedy, n 0 1 (1.1) 11 (11.8) four (four.three) 20 (21.five)26 (28.0) six (six.four)Age median (range) Girls, n Dosage, n Sufferers who completed the comply with up, n 87 (93.five) 91 (88.3) 178 (90.8) All discontinued therapy; 1 patient discontinued dabigatran; patients discontinued dabigatran; patient discontinued rivaroxaban; DOAC:Direct oral anticoagulants.SI MTotal (n)TIMinor bleeding (n)Mild epistaxis (2) Small subcutaneous haematomas (1) Subconjunctival haemorrhage (1)Blood Transfus 2018; 16: 209-14 DOI ten.MIP-4/CCL18, Human 2450/2017.CA125 Protein Accession 0196-16All rights reserved – For private use only No other use without having premissionExperience of DOAC in non valvular atrial fibrillationAdherence/satisfaction with therapy A total of 133 out of 178 individuals who completed the 1-year follow up (74.PMID:24238415 4 , median age 78 years, variety 50-94) answered the VAS questionnaire: 65 of 87 (74.7 ) patients on dabigatran (median age 76 years, variety 56-93) and 68 of 91 (74.7 ) on rivaroxaban (median age 79 years, range 50-94). All individuals showed excellent adherence for the new oral therapy and scored from a minimum of 7 to a maximum of ten (Figure 3). Patients on rivaroxaban assigned a higher score (imply 9.1, SD 1.0) than patients on dabigatran (mean 8.7; SD 0.9; Mann-Whitney U-test p=0.01).SI MTIFigure 2 – Cumulative event-free survival in DOAC anticoagulated patients.Kaplan-Meier curve, showing cumulative event-free survival in DOAC anticoagulated sufferers taking dabigatran (solid line) or rivaroxaban (dotted line). DOAC: direct oral anticoagulants.DiscussionDOAC represent an undisputed innovation as long-term oral anticoagulant therapy in individuals.